[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Enhancer of zeste homolog 2 protein inhibitors - Pipeline Insight, 2021

March 2021 | 60 pages | ID: EC256E6F8F86EN
DelveInsight

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

DelveInsight’s, “Enhancer of zeste homolog 2 protein inhibitors– Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Enhancer of zeste homolog 2 protein inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Enhancer of zeste homolog 2 protein inhibitors Understanding

Enhancer of zeste homolog 2 protein inhibitors: Overview

Enhancer of zeste homolog 2 is a component of the Polycomb repressive complex 2 that mediates chromatin-based gene silencing through trimethylation of lysine 27 on histone H3. This complex plays vital roles in the regulation of development-specific gene expression.

Function – Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene, that participates in histone methylation and, ultimately, transcriptional repression. EZH2 catalyzes the addition of methyl groups to histone H3 at lysine 27, by using the cofactor S-adenosyl-L-methionine. Mutation or over-expression of EZH2 has been linked to many forms of cancer. EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is up regulated in multiple cancers.

Enhancer of zeste homolog 2 protein inhibitors – EZH2 is upregulated in various cancers with high levels associated with metastatic cancer and poor prognosis. Dysregulation of the histone methyltransferase EZH2 plays a critical role in the development of a variety of malignancies including B-cell lymphomas.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs Chapters

This segment of the Enhancer of zeste homolog 2 protein inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Enhancer of zeste homolog 2 protein inhibitors Emerging Drugs
  • Tazemetostat: Epizyme, Inc.
Tazemetostat is a potent, selective, and orally bioavailable small-molecule inhibitor of EZH2 enzymatic activity. EZH2, a methyltransferase plays a role in epithelioid sarcoma pathogenesis. The drug is currently being evaluated in Phase III stage of dvelopemnt for the treatment of patients with Synovial cancer and various other solid tumors.
  • CPI-1205: Constellation Pharmaceuticals
CPI-1205 is a potent, selective EZH2 inhibitor that reduces global histone H3K27 trimethylation in a reversible way. The drug is currently being evaluated in Phase I/II stage of development in combination with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer.

Further product details are provided in the report…….

Enhancer of zeste homolog 2 protein inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Enhancer of zeste homolog 2 protein inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Enhancer of zeste homolog 2 protein inhibitors
There are approx. 10+ key companies which are developing the Enhancer of zeste homolog 2 protein inhibitors. The companies which have their Enhancer of zeste homolog 2 protein inhibitors drug candidates in the most advanced stage, i.e. Phase III include, Epizyme Inc.
  • Phases
DelveInsight’s report covers around 10+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Enhancer of zeste homolog 2 protein inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Enhancer of zeste homolog 2 protein inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Enhancer of zeste homolog 2 protein inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Enhancer of zeste homolog 2 protein inhibitors drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Enhancer of zeste homolog 2 protein inhibitors R&D. The therapies under development are focused on novel approaches for Enhancer of zeste homolog 2 protein inhibitors.
Enhancer of zeste homolog 2 protein inhibitors Report Insights
  • Enhancer of zeste homolog 2 protein inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Enhancer of zeste homolog 2 protein inhibitors Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Enhancer of zeste homolog 2 protein inhibitors drugs?
  • How many Enhancer of zeste homolog 2 protein inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Enhancer of zeste homolog 2 protein inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Enhancer of zeste homolog 2 protein inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Enhancer of zeste homolog 2 protein inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Enhancer of zeste homolog 2 protein inhibitors: Overview
  Structure
  Mechanism of Action
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Enhancer of zeste homolog 2 protein inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
  Enhancer of zeste homolog 2 protein inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Enhancer of zeste homolog 2 protein inhibitors Collaboration Deals
  Company-Company Collaborations (Licensing / Partnering) Analysis
  Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
  Comparative Analysis
Tazemetostat: Epizyme, Inc.
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
CPI-1205: Constellation Pharmaceuticals
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
  Comparative Analysis
PF 06821497: Pfizer
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
  Comparative Analysis
OR S1: Daiichi Sankyo
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Enhancer of zeste homolog 2 protein inhibitors Key Companies
Enhancer of zeste homolog 2 protein inhibitors Key Products
Enhancer of zeste homolog 2 protein inhibitors- Unmet Needs
Enhancer of zeste homolog 2 protein inhibitors- Market Drivers and Barriers
Enhancer of zeste homolog 2 protein inhibitors- Future Perspectives and Conclusion
Enhancer of zeste homolog 2 protein inhibitors Analyst Views
Enhancer of zeste homolog 2 protein inhibitors Key Companies
Appendix

LIST OF TABLES

Table 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products


LIST OF FIGURES

Figure 1 Total Products for Enhancer of zeste homolog 2 protein inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products


More Publications